172 related articles for article (PubMed ID: 38347552)
21. Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.
Byron SA; Hendricks WPD; Nagulapally AB; Kraveka JM; Ferguson WS; Brown VI; Eslin DE; Mitchell D; Cornelius A; Roberts W; Isakoff MS; Oesterheld JE; Wada RK; Rawwas J; Neville K; Zage PE; Harrod VL; Bergendahl G; VanSickle E; Dykema K; Bond J; Chou HC; Wei JS; Wen X; Reardon HV; Roos A; Nasser S; Izatt T; Enriquez D; Hegde AM; Cisneros F; Christofferson A; Turner B; Szelinger S; Keats JJ; Halperin RF; Khan J; Saulnier Sholler GL; Trent JM
Cancer Res; 2021 Dec; 81(23):5818-5832. PubMed ID: 34610968
[TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
Hartmann C; Weinel P; Schmid H; Grigull L; Sander A; Linderkamp C; Welte K; Reinhardt D
J Pediatr Hematol Oncol; 2011 Jul; 33(5):344-9. PubMed ID: 21572345
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
24. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
25. Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations.
Pastorino F; Capasso M; Brignole C; Giglio S; Bensa V; Cantalupo S; Lasorsa VA; Tondo A; Mura R; Sementa AR; Garaventa A; Ponzoni M; Amoroso L
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232538
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
27. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
[TBL] [Abstract][Full Text] [Related]
28. Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma.
Fathpour G; Jafari E; Hashemi A; Dadgar H; Shahriari M; Zareifar S; Jenabzade AR; Vali R; Ahmadzadehfar H; Assadi M
Clin Nucl Med; 2021 Jul; 46(7):540-548. PubMed ID: 33782280
[TBL] [Abstract][Full Text] [Related]
29. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.
Tran HC; Marachelian A; Venkatramani R; Jubran RF; Mascarenhas L
Pediatr Hematol Oncol; 2015 Feb; 32(1):26-31. PubMed ID: 25551355
[TBL] [Abstract][Full Text] [Related]
31. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
32. Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma.
Imaya M; Muramatsu H; Narita A; Yamamori A; Wakamatsu M; Yoshida T; Miwata S; Narita K; Ichikawa D; Hamada M; Nishikawa E; Kawashima N; Nishio N; Kojima S; Takahashi Y
Cancer Med; 2022 May; 11(9):1956-1964. PubMed ID: 35233973
[TBL] [Abstract][Full Text] [Related]
33. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor.
Wang J; Zhang L; Guo L; Que Y; Zhang Y; Sun F; Zhu J; Lu S; Huang J; Wu L; Cai R; Zhen Z; Zeng S; Zhang Y; Sun X
Front Oncol; 2021; 11():721564. PubMed ID: 34621673
[TBL] [Abstract][Full Text] [Related]
35. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318
[TBL] [Abstract][Full Text] [Related]
36. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).
Fox E; Mosse' YP; Meany HM; Gurney JG; Khanna G; Jackson HA; Gordon G; Shusterman S; Park JR; Cohn SL; Adamson PC; London WB; Maris JM; Balis FM
Pediatr Blood Cancer; 2014 Jun; 61(6):990-6. PubMed ID: 24347462
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
[TBL] [Abstract][Full Text] [Related]
38. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
39. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
40. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]